NCT02926326

The Effect of Azithromycin on BCT197 Exposure in Healthy Male Volunteers

An Open-label, Single-sequence Study to Evaluate the Effect of Azithromycin on BCT197 Exposure in Healthy Male Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Mereo BioPharma · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

An open-label, single-sequence study to evaluate the effect of azithromycin on BCT197 exposure in healthy male subjects.

Detailed description

This will be an open study conducted in healthy male subjects at a single centre. Each subject will participate in a screening visit and 2 study periods. At the first study period, all subjects will receive a single dose of BCT197 and at study period 2, all subjects will receive 3 daily doses of azithromycin and a single dose of BCT197.

Conditions

• Interaction

Interventions

Type	Name	Description
DRUG	BCT197	A single dose of BCT197
DRUG	Azithromycin	3 daily doses of Azithromycin

Timeline

• Start date: 2016-09-01
• Primary completion: 2016-10-01
• Completion: 2016-10-01
• First posted: 2016-10-06
• Last updated: 2016-10-24

Locations

1 site across 1 country: United Kingdom